Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.
Código da empresaRDY
Nome da EmpresaDr Reddy's Laboratories Ltd
Data de listagemJan 01, 1986
CEOMr. Deepak Sapra
Número de funcionários27811
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 01
Endereço8-2-337, Road No.3 Banjara Hills
CidadeHYDERABAD
Bolsa de valoresAustralian Stock Exchange Ltd
PaísIndia
Código postal500034
Telefone914049002900
Sitehttps://www.drreddys.com/
Código da empresaRDY
Data de listagemJan 01, 1986
CEOMr. Deepak Sapra
Um total de
332.70M
USD foi distribuído em dividendos nos últimos 5 anos.
RDY.NB Final Cash Dividend of gross USD 0.476153 paid on Aug 12, 2024 going ex on Jul 30, 2024
RDY.NB Final Cash Dividend of gross USD 0.482608 paid on Aug 11, 2023 going ex on Jul 28, 2023
RDY.NB Final Cash Dividend of gross USD 0.378434 paid on Aug 12, 2022 going ex on Aug 01, 2022
RDY.NB Final Cash Dividend of gross USD 0.336485 paid on Aug 11, 2021 going ex on Jul 30, 2021
RDY.NB Final Cash Dividend of gross USD 0.333364 paid on Aug 17, 2020 going ex on Jul 10, 2020